
    
      In Part A, participants will receive 4 weeks MGN1703 therapy (60 mg s.c. twice weekly).
      During the 4 weeks, participants will be closely monitored for safety and therapeutic effects
      of the drug. Targeted enrolment in Part A is 14-16 study subjects.

      In Part B, participants will receive 24 weeks of MGN1703 therapy (60 mg s.c. twice weekly).
      During the 24 weeks, participants will be frequently monitored for safety and therapeutic
      effects of the drug. Targeted enrolment in Part B is 10-12 study subjects, preferentially
      recruited from part A.
    
  